Fulham Introduces Universal Voltage Version of Integrated DirectAC LED Engine and Retrofit Kit

New Universal Voltage DirectAC LED Features Integrated Driver and is Suitable for Open and Closed Luminaires With or Without Lenses.

Hawthorne, CA, USA -- Fulham Co., Inc., a leading supplier of lighting sub-systems and electronics for commercial and specialty applications, today announced the release of universal voltage versions of its DirectAC direct-drive LED units. The DirectAC LED Engines were released earlier this year in a 120V and with this product release, the same low-profile, self-contained LED engine with integrated driver is now available in a new unit that can support power ratings from 120 to 277 volts.

The DirectAC LED Engine was designed with the driver integrated on the circuit board, resulting in a cost-efficient, highly reliable lighting solution suitable for use in wall sconces or ceiling luminaires, either as new lighting installations or retrofits. The integrated LED driver makes for an extremely low profile, and now with universal voltage support, the same unit can be installed in virtually any setting. The Universal DirectAC LED Engine is suitable for open and enclosed luminaires, and luminaires with plastic and glass lenses.

"More of our customers are working on large construction and retrofit projects with multiple luminaire types, so we are seeing more demand for one-size-fits-all LED light kits," said Edwin Reyes, Product Director, LED Light Sources, for Fulham. "The Universal DirectAC LED Engine is designed to provide a single, self-contained, low-profile lighting solution that can be installed anywhere in five to 10 minutes."

The DirectAC LED Engines are available in 10, 15W, 23W, and 34W round configurations as well as a 15W, 4 by 7-inch rectangular configuration. The DirectAC LED Engines offer a lumen maintenance of L70>54,000 hours, with a color consistency of 3 SDCM and a variety of color temperatures with an 80 CRI up to 90 CRI, making them ideal for replacing fluorescents. The units are leading/trailing edge dimmable from 100 to 10 percent. To reduce flicker, the DirectAC Engines have additional circuitry for use with 50/60 Hz power lines; flicker is below 30 percent when operated at line voltage meeting the CEC requirement for low flicker.

All units are suitable for installation in dry and damp locations, indoor or outdoor. The units are cURus, cULus Classified and ENERGY STAR® Luminaire 2.0 listed so they qualify for most rebate programs.

The Universal DirectAC LED Engines are available from Fulham locations worldwide. For more information, visit http://www.fulham.com.

About Fulham
Fulham Co., Inc. is a leading global provider of intelligent, socially-conscious sustainable commercial lighting components, sub-systems, and electronics for use in commercial general lighting, parking structure, signage, horticultural, UV and other applications. The company develops and manufactures a variety of award-winning LED and emergency products, as well as legacy products across multiple lighting platforms. Fulham sells its lighting solutions worldwide through original equipment manufacturers (OEMs) and electrical equipment distribution channels. Headquartered in Hawthorne, Calif., the company has sales and/or manufacturing facilities in the Netherlands, China, India and the UAE. For more information, visit http://www.fulham.com.

Media Contact:
Andy Firchau
Marketing Manager
Fulham Co., Inc.
Phone: +1 (323) 779-2980, ext. 1252

Graphic Inspector Now Supports macOS High Sierra: Image, Vector Checkup

Zevrix Solutions announces Graphic Inspector 2.4, a compatibility update to company's quality control solution for images and Adobe Illustrator files. Graphic Inspector can quickly locate documents with specific resolution, color, spot channels, fonts and other attributes. The app can is the only tool on the market that can check both images and vector files. With the new version Graphic Inspector is upgraded to 64-bit architecture and introduces support for the upcoming macOS 10.13 High Sierra.

Toronto (ON), Canada -- Zevrix Solutions today announces the release of Graphic Inspector 2.4, a compatibility update to company's quality control solution for images and vector graphic files. Graphic Inspector can check entire folders of documents for potential problems according to specific workflow requirements. The app is the only tool on the market that lets graphics industry professionals inspect both raster images and Adobe Illustrator documents.

The new version introduces support for the upcoming macOS 10.13 High Sierra and is offered as a free update to licensed customers. Graphic Inspector is now also upgraded to 64-bit architecture, which improves the app's performance and reduces the likelihood of memory-related errors when working with large images.

"I'm surprised no one else thought of it before: to display every bit of useful information about vector or raster graphic files and flag the ones that match rules you define," writes Jay Nelson in Layers magazine. "With its combination of price, utility, and thoughtful design, Graphic Inspector is a rare gem."

Graphic Inspector is designed to help users of any trade, whether it's print, prepress, web design, electronic publishing or digital photography. For example, users can quickly locate files whose color mode is CMYK, format - TIFF, resolution is below 300 dpi, ICC profile isn't "US Web Coated" and so on.

Graphic Inspector offers the following key features:

-Customizable checkup presets
-Common checks such as resolution, color mode, ICC profile and file size
-Professional prepress checks: spot colors, fonts in vector files, image compression and more

Pricing and Availability:
Graphic Inspector can be purchased from the Zevrix web site for US$19.95, as well as from authorized resellers. Graphic Inspector is free with purchase of PDF Checkpoint or InPreflight Pro for Adobe InDesign. Trial is also available for download. The update is free for users of version 2 ($10 to upgrade from version 1). Graphic Inspector requires macOS 10.7-10.13.

About Zevrix Solutions
Located in Toronto, Canada, Zevrix Solutions provides productivity solutions for Adobe Creative Suite software, PDF and graphic file diagnostics, file delivery, and Microsoft Office on Mac OS. Zevrix is dedicated to help professionals increase their profits through automating everyday tasks, producing error-free documents, saving disk space and cutting production costs. For more information, visit http://www.zevrix.com.

Leo Revzin
Zevrix Solutions
105 McCAUL St, Suite 301
Toronto Ontario M5T 2X4 Canada

Landmark Asthma Study Demonstrates Device Choice Determines Asthma Control

Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration.

Plattsburgh, NY, USA -- Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Research has shown that even when using the same metered-dose inhaler (MDI), not all valved holding chambers perform equally well.[1]

A landmark real-world study involving more than 18,000 asthma patients has demonstrated superior asthma control with the AEROCHAMBER PLUS® FLOW-VU® antistatic Valved Holding Chamber (VHC) compared with other chamber devices.[2] According to the study, published in Pulmonary Therapy, use of the AEROCHAMBER PLUS® FLOW-VU® antistatic chamber resulted in delayed time to first exacerbation, fewer asthma-related emergency department visits, and lower exacerbation-related costs than control chambers.

Asthma is a common respiratory condition that affects an estimated 24.6 million people in the United States. Almost half of them, including nearly 3 million children, experience one or more asthma attack in a year.[3]

As opposed to systemic medications, inhalation is the recommended way to administer asthma medications because it directly targets the drug to the lungs while reducing potential side effects. Inhaled corticosteroids and bronchodilators administered by MDIs are the mainstay of long-term asthma treatment, the goals of which are to improve symptoms and prevent the occurrence of exacerbations.[4]

Poor inhaler operation by users is common, resulting in less of the delivered drug reaching the lungs. Instead, much of it is deposited on the back of the throat (oropharyngeal deposition) and then swallowed.[5] Research shows that between 28% and 68% of patients do not use inhalers well enough to benefit from prescribed medication.[6] In addition, 25% of costs associated with inhalers is wasted due to poor inhaler technique.[6]

Chambers are designed to reduce oropharyngeal deposition by changing the particle size distribution of the inhaled aerosol, and by holding the aerosol in the chamber until the patient is ready to inhale, which reduces the need for good coordination between inhalation and inhaler actuation.[7] Effectiveness of these devices can be adversely affected by the design, including the chamber electrostatic charge, a commonly reported cause of inconsistent medication delivery.[8]

Global respiratory guidelines recommend the use of chambers to improve MDI drug delivery.[4] American Thoracic Society and American Association for Respiratory Care Clinical Practice Guidelines state that the addition of a chamber is recommended and helpful.[9,10] Research also indicates that patients who use a chamber with an MDI have better asthma control than those using an MDI alone.[11]

In this new study, Dr. Chakkarin Burudpakdee (QuintilesIMS, Fairfax, VA, USA) and colleagues compared the effects of the antistatic AEROCHAMBER PLUS® FLOW-VU® aVHC and control chambers on treatment outcomes, resource use, and healthcare costs in a real-world asthma population.[2] More than 18,000 patients were included from an adjudicated claims database containing medical and pharmacy claims for more than 150 million U.S. health plan members.[2]

The analysis showed that among patients with at least 30 days of follow-up, those using the AEROCHAMBER PLUS® FLOW-VU® antistatic VHC experienced a delay in the time to first exacerbation and had fewer asthma-related emergency room visits. In addition, exacerbation-related costs were lower when compared to those using the control (non-antistatic) chambers.[2] A trend toward lower exacerbation rates per patient for the AEROCHAMBER PLUS® FLOW-VU® aVHC was sustained throughout the 12 months of the study.[2]

"This landmark study using a large volume of real-world evidence generated from thousands of patients shows the value of optimizing drug delivery in asthma management and further supports that chambers are not interchangeable," said co-author Dominic Coppolo, MBA, RRT, FAARC, Vice President Clinical Strategy and Development. "The reduction in exacerbation incidents among users of the AEROCHAMBER PLUS® FLOW-VU® chamber is particularly notable because experiencing an exacerbation is a risk factor for future exacerbation events-and minimizing exacerbation risk is a key goal of treatment."

"The European Medicines Agency recommended in 2009 that development of a MDI should include the testing of at least one specific, named chamber, and that any substitution must be supported by appropriate in vitro or clinical data demonstrating equivalence," he said. "We presented laboratory data at the recent Respiratory Drug Delivery Europe meeting[2] that confirmed that not all chambers perform equally well with the same MDI, which underlines the importance of recognizing the impact and potential risks of substituting one device for another."

About Monaghan Medical Corporation
Monaghan Medical Corporation (MMC) offers leading aerosol drug delivery devices and respiratory management products including AeroEclipse® II BAN, AeroChamber Plus® aVHC and the Aerobika® device exclusively in the United States. MMC's strength lies in product development around core capabilities in mechanical design complimented by collaboration with a state-of-the-art aerosol research laboratory. MMC focuses on developing cost-efficient, outcome-based solutions for its customers. (http://www.monaghanmed.com)

About AEROCHAMBER® brand valved holding chambers, including the AEROCHAMBER PLUS® FLOW-VU® anti-static chamber
Developed in 1983 to address the needs of asthma and COPD patients having difficulty in taking their MDI medications correctly, the AEROCHAMBER® brand of chamber has innovated continuously to improve patient ease of use and quality of life as well as clinical outcomes and healthcare system savings.

The AEROCHAMBER PLUS® valved holding chamber is the leading global chamber brand, with safety and efficacy validated in numerous third-party clinical evaluations among various patient populations. It is the chamber most recommended by leading MDI pharmaceutical companies.
AEROCHAMBER PLUS® FLOW-VU® chamber is an antistatic chamber designed to deliver the intended prescribed dose via the MDI, similar to using an MDI with perfect technique. An additional feature is the incorporation of the FLOW-VU® inhalation indicator for the caregiver to observe effective inhalation. A recent study showed that caregiver quality of life improved almost four-fold when using the AEROCHAMBER PLUS® chamber with FLOW-VU® indicator versus the same chamber without the indicator.[12] The FLOW-VU® indicator provides real-time feedback confirming an effective inhalation and that there are no leakages of ambient air into the space between facemask and face, which could prevent medication delivery altogether. (http://www.monaghanmed.com/AeroChamber-Plus-Flow-Vu-aVHC2)

About the study
Data for more than 18,000 patients with an asthma diagnosis were analysed from the QuintilesIMS Real-World Data Adjudicated Claims Database (PharMetrics Plus) between 1/2010 and 8/2015-9,325 using the AEROCHAMBER PLUS® FLOW-VU® antistatic VHC and a propensity-matched comparison cohort of 9,325 non-antistatic VHCs. Exacerbation incident rates (IR), time to first exacerbation using Kaplan-Meier survival analysis, occurrence of exacerbations, and healthcare resource use and costs were compared.

Exacerbation IR/100 person-days (95% CI) was significantly higher in the control device cohort than the antistatic chamber cohort (0.161 [0.150-0.172] vs.0.137 [0.128-0.147]); more patients in the antistatic chamber cohort remained exacerbation free.
4,293 patients in each cohort were followed up for (greater than or equal to)12 months, during which there was a trend for patients in the antistatic VHC group to be less likely (10-12%) to experience an exacerbation. Fewer patients using the antistatic VHC had an ED visit compared with those in the control group (10.8% vs. 12.4%).
Exacerbation-related costs for the antistatic VHC cohort were 23%, 25%, 20%, and 12% lower than the control device cohort at 1, 6, 9, and 12 months, respectively.

For clinical inquiries, please contact:
Dominic P. Coppolo, MBA, RRT, FAARC
Vice President Clinical Strategy and Development
Monaghan Medical Corporation

Words or phrases accompanied by ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation. © 2017 Monaghan Medical Corporation.


1 Nagel MW, Suggett JA. Equivalence evaluation of valved holding chambers (VHCs) with albuterol pressurized metered dose inhaler (pMDI). Respiratory Drug Delivery Europe; April 25-28, 2017, 2017; Nice, France.

2 Burudpakdee C, Kushnarev V, Coppolo D, Suggett J. A retrospective study of the effectiveness of the AeroChamber Plus® Flow-Vu® Antistatic Valved Holding Chamber for asthma control. Pulmonary Therapy. 2017. http://doi.org/10.1007/s41030-017-0047-1. Accessed July 14.

3 Asthma Facts. United States Environmental Protection Agency. EPA-402-F-04-019. May 2017.

4 Global Initiative for Asthma: Global strategy for asthma management and prevention, 2017. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention Accessed November 2017.

5 Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respiratory Medicine. 2013;107(1):37-46.

6 Fink JB, Rubin BK. Problems with Inhaler Use: A Call for Improved Clinician and Patient Education. Respir Care 2005;50(10):1360-74.

7 Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert opinion on drug delivery. 2009;6(1):91-102.

8 Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respiratory care. 2007;52(3):283-300.

9 Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal 2014 ;43:343-373.

10 Ari A, et al. Aerosol Delivery Device Selection for Spontaneously Breathing Patients:2012. Respir Care 2012;57(4):613- 626.

11 Levy ML, et al. Asthma patients' inability to use a pressurized metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the Global Initiative for Asthma (GINA) strategy: a retrospective analysis. Prim Care Respir J. 2013; Dec;22(4):406-11.

12 Ammari WG, et al. Evaluation of asthma control, parents' quality of life and preference between AeroChamber Plus and AeroChamber Plus Flow-Vu spacers in young children with asthma. J Asthma 2015; 52(3):301-7.